Issue 4 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

28

No.

4

April 29, 2005Apr 29, 2005

Free

DOWNLOAD THE PDF

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

U.S., Canada Begin ExCel Trial To Evaluate Aromasin For Breast Cancer Prevention

Avastin Improves PFS In Advanced Breast Cancer

Preoperative Drug Combo Benefits HER-2 Breast Cancer

Combination Radiation/Vaccine May Benefit Some Patients

“Inoperable” Prostate Cancer May Be Operable, Curable

Benefit Seen In Novel Drug That Treats Gleevec Resistance

NCI’s Rosenberg Confirms 2002 Immunotherapy Results

NCI-Approved Clinical Trials

Recent Issues

Volume 52 | Issue 41 - November 06, 2026

Volume 52 | Issue 40 - October 30, 2026

Volume 52 | Issue 39 - October 23, 2026

Volume 52 | Issue 38 - October 16, 2026

Volume 52 | Issue 37 - October 09, 2026

Volume 52 | Issue 36 - October 02, 2026